Long‐term postoperative effects of administration of allogeneic blood products in 104 dogs with hemangiosarcoma

Objective To determine the influence of administering allogeneic blood products (ABP) on the progression of hemangiosarcoma in dogs. Study design Multi‐institutional, retrospective study. Sample population One hundred four dogs with hemangiosarcoma that survived until postoperative discharge from th...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Veterinary surgery 2018-11, Vol.47 (8), p.1039-1045
Hauptverfasser: Ciepluch, Brittany J., Wilson‐Robles, Heather M., Pashmakova, Medora B., Budke, Christine M., Ellison, Gary W., Thieman Mankin, Kelley M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective To determine the influence of administering allogeneic blood products (ABP) on the progression of hemangiosarcoma in dogs. Study design Multi‐institutional, retrospective study. Sample population One hundred four dogs with hemangiosarcoma that survived until postoperative discharge from the hospital. Methods Medical records of dogs that had been operated on for hemoangiosarcoma were reviewed for signalment, presence of a hemoabdomen, presence of metastatic disease, and whether the dog had received chemotherapy or Yunnan Baiyao. Data that were collected were compared between dogs that received perioperative ABP and those that did not. Disease‐free interval was compared between groups. The Kaplan‐Meier method was used to obtain univariate descriptive statistics for time to clinical decline. A multivariable Cox regression model was used to analyze association or effect of potential predictor variables. Results The median disease‐free interval (DFI) was shorter in the 67 dogs that received a blood transfusion (76 days; range, 1‐836) than in the 37 dogs that did not receive a blood transfusion (120 days; range, 38‐916). According to the multivariable Cox regression model, administration of blood products (P = .04) and the presence of gross metastatic disease at the time of surgery (P 
ISSN:0161-3499
1532-950X
DOI:10.1111/vsu.12967